Intravenous (IV) Iron Drugs Market
Intravenous (IV) Iron Drugs Market Size, Share & Trends Analysis Report by Product Type (Iron Dextran, Ferric Carboxymaltose, Iron Sucrose, and Ferric Gluconate), and by Application (Oncology, Nephrology, Gastroenterology, Obstetrics and Gynecology, Cardiology, and Others), Forecast Period (2026-2035)
Industry Overview
Intravenous (IV) iron drugs market was valued at $2.82 billion in 2025 and is projected to reach $5.38 billion by 2035, growing at a CAGR of 6.7% during the forecast period (2026-2035). The market is growing due to the rising clinical burden of iron deficiency anemia, particularly among patients with chronic kidney disease and cancer who require rapid and reliable iron repletion. Increasing use of intravenous formulations such as ferric carboxymaltose and iron sucrose in nephrology and oncology settings reflects a shift toward hospital-administered therapies that provide faster hematologic response compared to oral alternatives. A second major driver is the expanding diagnosis and treatment of anemia in obstetrics and gynecology, where intravenous iron is increasingly preferred for moderate to severe cases during pregnancy and postpartum care. Improvements in formulation safety profiles, including reduced risk of hypersensitivity reactions with newer compounds, have strengthened physician confidence and supported broader adoption across gastroenterology and cardiology indications.
Market Dynamics
Increasing Adoption of Ferric Carboxymaltose and Novel Formulations
The market is witnessing growing adoption of ferric carboxymaltose and other newer intravenous iron formulations due to their ability to deliver higher doses in a single administration. This trend is particularly evident in oncology and nephrology settings, where rapid correction of iron deficiency is critical to patient outcomes. Healthcare providers are favoring these formulations for their convenience, shorter infusion times, and improved safety profiles compared with traditional iron dextran. The broader clinical acceptance is driving product differentiation and encouraging hospitals and infusion centers to integrate advanced IV iron therapies into standard treatment protocols. As a result, manufacturers are investing in expanding supply and distribution networks to meet increasing demand across key regions.
Expansion in Emerging Markets and Hospital Infrastructure
Emerging markets are contributing to the growth of the intravenous iron drugs market as healthcare infrastructure improves and access to hospital-based treatments expands. The rising prevalence of anemia, particularly in Asia-Pacific and Latin America, has prompted healthcare providers to prioritize intravenous therapy for faster correction and enhanced patient compliance. Increasing investment in hospitals and specialty infusion centers supports the introduction of IV iron therapies for a wider range of indications, including cardiology and gastroenterology. Additionally, awareness campaigns and clinical guidelines promoting intravenous iron for moderate to severe anemia are reinforcing adoption. This trend is creating new revenue opportunities for manufacturers and encouraging strategic market expansion initiatives.
Market Segmentation
- Based on the product type, the market is segmented into iron dextran, ferric carboxymaltose, iron sucrose, and ferric gluconate.
- Based on the application, the market is segmented into oncology, nephrology, gastroenterology, obstetrics and gynecology, cardiology, and others.
Ferric Carboxymaltose Driving Growth in Product Type Segment
Ferric carboxymaltose is emerging as a leading product type in the intravenous iron drugs market due to its ability to deliver large single doses rapidly, reducing the need for multiple infusions. This feature is particularly valuable in oncology and nephrology, where patients require swift correction of iron deficiency to support ongoing treatments such as chemotherapy or dialysis. Enhanced safety profiles and lower risk of hypersensitivity reactions compared with older formulations, like iron dextran, have increased physician confidence in its use. Ongoing clinical adoption across hospital and outpatient settings is further accelerating uptake. Consequently, ferric carboxymaltose is establishing itself as a key revenue driver within the global product portfolio.
Oncology as a Key Application Segment Driving Market Expansion
The oncology sub-segment is a major contributor to the growth of the intravenous iron drugs market, driven by the high prevalence of chemotherapy-induced anemia among cancer patients. Intravenous iron therapies, especially ferric carboxymaltose and iron sucrose, provide rapid replenishment of iron stores, which supports hemoglobin recovery and reduces the need for blood transfusions. Hospitals and cancer care centers are increasingly integrating IV iron into standard treatment protocols to improve patient outcomes and maintain treatment schedules. Regulatory approvals and clinical guidelines endorsing IV iron for chemotherapy-related anemia have reinforced adoption. This focus on oncology is creating sustained demand across multiple IV iron products and strengthening market expansion.
Regional Outlook
The global Intravenous (IV) iron drugs market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).
North America Leading the Global Intravenous (IV) Iron Drugs Market
North America remains the leading region in the intravenous iron drugs market, supported by a well-established healthcare infrastructure and high adoption of advanced IV iron formulations such as ferric carboxymaltose and iron sucrose. The prevalence of chronic kidney disease, oncology-related anemia, and other iron deficiency conditions drives consistent demand across hospitals and outpatient infusion centers. Strong reimbursement frameworks and widespread clinical guideline endorsements facilitate broader use of IV iron therapies. Key industry participants active in the region include CSL Limited (CSL Vifor), Sanofi S.A., AbbVie Inc., and Fresenius SE & Co. KGaA, each maintaining extensive product portfolios. Recent approvals of high-dose, rapid-infusion formulations have further reinforced market growth and expanded treatment access.
Asia-Pacific as the Fastest Growing Region in the Global Intravenous (IV) Iron Drugs Market
Asia-Pacific is emerging as the fastest-growing region for intravenous iron drugs due to rising awareness of anemia management, increasing hospital infrastructure, and rapid adoption of IV therapies in India, China, and Japan. Expansion of specialty infusion centers and improved access to advanced formulations, such as ferric carboxymaltose and iron sucrose, is accelerating adoption among oncology and nephrology patients. The growing prevalence of iron deficiency anemia in obstetrics and gynecology is also contributing to increased demand. Prominent players such as CSL Limited (CSL Vifor), Pharmacosmos A/S, and Fresenius Kabi are actively expanding distribution networks in the region. The combination of increasing patient awareness, healthcare investment, and clinical adoption is driving strong double-digit growth rates in Asia-Pacific.
Market Players Outlook
The major companies operating in the global intravenous (IV) iron drugs market include AbbVie Inc., CSL Ltd. (CSL Vifor), Daiichi Sankyo Company, Ltd., Fresenius SE & Co. KGaA, Sanofi S.A., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.
Recent Developments
- In August 2025, Amphastar Pharmaceuticals announced FDA approval of its ANDA for Iron Sucrose Injection in multiple dosages (50mg/2.5mL, 100mg/5mL, 200mg/10mL) single-dose vials. This iron replacement product treats iron deficiency anemia in chronic kidney disease patients.
- In August 2025, Viatris Inc. received FDA approval for Iron Sucrose Injection, USP, an IV iron therapy for treating iron deficiency anemia in adults and children (2+ years) with chronic kidney disease. This first generic version of Venofer comes in 50 mg, 100 mg, and 200 mg single-dose vials.
- In March 2024, CSL Vifor announced that Health Canada approved Ferinject (ferric carboxymaltose) for IV treatment of iron deficiency anemia in patients aged one year and older when oral iron is ineffective or not tolerated. It is also approved for treating iron deficiency in adults with heart failure (NYHA class II/III) to improve exercise capacity.
The Report Covers
- Market value data analysis of 2025 and forecast to 2035.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global intravenous (IV) iron drugs market. Based on the availability of data, information related to new products and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
- Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Global Intravenous (IV) Iron Drugs Market Sales Analysis – Product Type | Application ($ Million)
- Intravenous (IV) Iron Drugs Market Sales Performance of Top Countries
- Research Methodology
- Primary Research Approach
- Secondary Research Approach
- Market Snapshot
- Market Overview and Insights
- Scope of the Study
- Analyst Insight & Current Market Trends
- Key Intravenous (IV) Iron Drugs Market Trends
- Market Recommendations
- Porter's Five Forces Analysis for the Intravenous (IV) Iron Drugs Market
- Competitive Rivalry
- Threat of New Entrants
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Market Determinants
- Market Drivers
- Drivers For Global Intravenous (IV) Iron Drugs Market: Impact Analysis
- Market Pain Points and Challenges
- Restraints For Global Intravenous (IV) Iron Drugs Market: Impact Analysis
- Market Opportunities
- Opportunities For Global Intravenous (IV) Iron Drugs Market: Impact Analysis
- Market Drivers
- Competitive Landscape
- Competitive Dashboard – Intravenous (IV) Iron Drugs Market Revenue and Share by Manufacturers
- Intravenous (IV) Iron Drugs Product Comparison Analysis
- Top Market Player Ranking Matrix
- Key Company Analysis
- AbbVie Inc.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- CSL Ltd. (CSL Vifor)
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Daiichi Sankyo Company, Ltd.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Fresenius SE & Co. KGaA (Fresenius Kabi division)
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Sanofi S.A.
- Overview
- Product Portfolio
- Financial Analysis
- SWOT Analysis
- Business Strategy
- Top Winning Strategies by Market Players
- Merger and Acquisition
- Product Launch
- Partnership And Collaboration
- AbbVie Inc.
- Key Company Analysis
- Global Intravenous (IV) Iron Drugs Market Sales Analysis by Product Type ($ Million)
- Iron Dextran
- Ferric Carboxymaltose
- Iron Sucrose
- Ferric Gluconate
- Global Intravenous (IV) Iron Drugs Market Sales Analysis by Application ($ Million)
- Oncology
- Nephrology
- Gastroenterology
- Obstetrics and Gynecology
- Cardiology
- Others
- Regional Analysis
- North American Intravenous (IV) Iron Drugs Market Sales Analysis – Product Type | Application | Country ($ Million)
- Macroeconomic Factors for North America
- United States
- Canada
- European Intravenous (IV) Iron Drugs Market Sales Analysis – Product Type | Application | Country ($ Million)
- Macroeconomic Factors for Europe
- UK
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia-Pacific Intravenous (IV) Iron Drugs Market Sales Analysis – Product Type | Application | Country ($ Million)
- Macroeconomic Factors for Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- Rest of Asia-Pacific
- Rest of the World Intravenous (IV) Iron Drugs Market Sales Analysis – Product Type | Application | Country ($ Million)
- Macroeconomic Factors for Rest of the World
- Latin America
- Middle East and Africa
- Company Profiles
- AbbVie Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Akebia Therapeutics, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Allergan plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- American Regent, Inc. (Injectafer / Venofer)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- CSL Ltd. (CSL Vifor)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Daiichi Sankyo Company, Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Fresenius SE & Co. KGaA (Fresenius Kabi division)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Luitpold Pharmaceuticals, Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Novartis AG
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pfizer Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Pharmacosmos A/S (Monofer / Cosmofer)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Rockwell Medical, Inc. (Triferic)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sanofi S.A. (Ferrlecit)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Shield Therapeutics Plc
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Sun Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Takeda Pharmaceutical Company Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Teva Pharmaceutical Industries Ltd.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Baxter International Inc.
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- Zydus Cadila (Zydus Group)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AMAG Pharmaceuticals, Inc. (Feraheme)
- Quick Facts
- Company Overview
- Product Portfolio
- Business Strategies
- AbbVie Inc.
1. Global Intravenous (IV) Iron Drugs Market Research and Analysis by Product Type, 2025–2035 ($ Million)
2. Global Iron Dextran Market Research and Analysis by Region, 2025–2035 ($ Million)
3. Global Ferric Carboxymaltose Market Research and Analysis by Region, 2025–2035 ($ Million)
4. Global Iron Sucrose Market Research and Analysis by Region, 2025–2035 ($ Million)
5. Global Ferric Gluconate Market Research and Analysis by Region, 2025–2035 ($ Million)
6. Global Intravenous (IV) Iron Drugs Market Research and Analysis by Application, 2025–2035 ($ Million)
7. Global Intravenous (IV) Iron Drugs in Oncology Market Research and Analysis by Region, 2025–2035 ($ Million)
8. Global Intravenous (IV) Iron Drugs in Nephrology Market Research and Analysis by Region, 2025–2035 ($ Million)
9. Global Intravenous (IV) Iron Drugs in Gastroenterology Market Research and Analysis by Region, 2025–2035 ($ Million)
10. Global Intravenous (IV) Iron Drugs in Obstetrics and Gynecology Market Research and Analysis by Region, 2025–2035 ($ Million)
11. Global Intravenous (IV) Iron Drugs in Cardiology Market Research and Analysis by Region, 2025–2035 ($ Million)
12. Global Intravenous (IV) Iron Drugs in Others Application Market Research and Analysis by Region, 2025–2035 ($ Million)
13. Global Intravenous (IV) Iron Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
14. North American Intravenous (IV) Iron Drugs Market Research and Analysis by Country, 2025–2035 ($ Million)
15. North American Intravenous (IV) Iron Drugs Market Research and Analysis by Product Type, 2025–2035 ($ Million)
16. North American Intravenous (IV) Iron Drugs Market Research and Analysis by Application, 2025–2035 ($ Million)
17. European Intravenous (IV) Iron Drugs Market Research and Analysis by Country, 2025–2035 ($ Million)
18. European Intravenous (IV) Iron Drugs Market Research and Analysis by Product Type, 2025–2035 ($ Million)
19. European Intravenous (IV) Iron Drugs Market Research and Analysis by Application, 2025–2035 ($ Million)
20. Asia-Pacific Intravenous (IV) Iron Drugs Market Research and Analysis by Country, 2025–2035 ($ Million)
21. Asia-Pacific Intravenous (IV) Iron Drugs Market Research and Analysis by Product Type, 2025–2035 ($ Million)
22. Asia-Pacific Intravenous (IV) Iron Drugs Market Research and Analysis by Application, 2025–2035 ($ Million)
23. Rest of the World Intravenous (IV) Iron Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
24. Rest of the World Intravenous (IV) Iron Drugs Market Research and Analysis by Product Type, 2025–2035 ($ Million)
25. Rest of the World Intravenous (IV) Iron Drugs Market Research and Analysis by Application, 2025–2035 ($ Million)
1. Global Intravenous (IV) Iron Drugs Market Share by Product Type, 2025 vs 2035 (%)
2. Global Iron Dextran Market Share by Region, 2025 vs 2035 (%)
3. Global Ferric Carboxymaltose Market Share by Region, 2025 vs 2035 (%)
4. Global Iron Sucrose Market Share by Region, 2025 vs 2035 (%)
5. Global Ferric Gluconate Market Share by Region, 2025 vs 2035 (%)
6. Global Intravenous (IV) Iron Drugs Market Share by Application, 2025 vs 2035 (%)
7. Global Intravenous (IV) Iron Drugs in Oncology Market Share by Region, 2025 vs 2035 (%)
8. Global Intravenous (IV) Iron Drugs in Nephrology Market Share by Region, 2025 vs 2035 (%)
9. Global Intravenous (IV) Iron Drugs in Gastroenterology Market Share by Region, 2025 vs 2035 (%)
10. Global Intravenous (IV) Iron Drugs in Obstetrics and Gynecology Market Share by Region, 2025 vs 2035 (%)
11. Global Intravenous (IV) Iron Drugs in Cardiology Market Share by Region, 2025 vs 2035 (%)
12. Global Intravenous (IV) Iron Drugs in Other Application Market Share by Region, 2025 vs 2035 (%)
13. Global Intravenous (IV) Iron Drugs Market Research and Analysis by Region, 2025–2035 ($ Million)
14. US Intravenous (IV) Iron Drugs Market Size, 2025–2035 ($ Million)
15. Canada Intravenous (IV) Iron Drugs Market Size, 2025–2035 ($ Million)
16. UK Intravenous (IV) Iron Drugs Market Size, 2025–2035 ($ Million)
17. France Intravenous (IV) Iron Drugs Market Size, 2025–2035 ($ Million)
18. Germany Intravenous (IV) Iron Drugs Market Size, 2025–2035 ($ Million)
19. Italy Intravenous (IV) Iron Drugs Market Size, 2025–2035 ($ Million)
20. Spain Intravenous (IV) Iron Drugs Market Size, 2025–2035 ($ Million)
21. Russia Intravenous (IV) Iron Drugs Market Size, 2025–2035 ($ Million)
22. Rest of Europe Intravenous (IV) Iron Drugs Market Size, 2025–2035 ($ Million)
23. India Intravenous (IV) Iron Drugs Market Size, 2025–2035 ($ Million)
24. China Intravenous (IV) Iron Drugs Market Size, 2025–2035 ($ Million)
25. Japan Intravenous (IV) Iron Drugs Market Size, 2025–2035 ($ Million)
26. South Korea Intravenous (IV) Iron Drugs Market Size, 2025–2035 ($ Million)
27. Australia and New Zealand Intravenous (IV) Iron Drugs Market Size, 2025–2035 ($ Million)
28. ASEAN Economies Intravenous (IV) Iron Drugs Market Size, 2025–2035 ($ Million)
29. Rest of Asia-Pacific Intravenous (IV) Iron Drugs Market Size, 2025–2035 ($ Million)
30. Latin America Intravenous (IV) Iron Drugs Market Size, 2025–2035 ($ Million)
31. Middle East and Africa Intravenous (IV) Iron Drugs Market Size, 2025–2035 ($ Million)
- Printable version
- No restriction to number of user within the company
Contact Sales
FAQS
The size of the Intravenous (IV) Iron Drugs Market in 2025 is estimated to be around $2.82 billion.
North America holds the largest share in the Intravenous (IV) Iron Drugs Market.
Leading players in the Intravenous (IV) Iron Drugs Market include AbbVie Inc., CSL Ltd. (CSL Vifor), Daiichi Sankyo Company, Ltd., Fresenius SE & Co. KGaA, Sanofi S.A., among others.
The Intravenous (IV) Iron Drugs Market is expected to grow at a CAGR of 6.7% from 2026 to 2035.
The Intravenous (IV) Iron Drugs Market growth is driven by increasing prevalence of iron deficiency anemia and rising demand for rapid and effective parenteral iron supplementation therapies.
